Taysha Gene Therapies
VerifiedOn a mission to eradicate monogenic CNS disease.
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$543m (Public information from May 2024)
Share price
$3.43 TSHA
Dallas Texas (HQ)
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | - | 518 % | (40 %) | (45 %) | 907 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | - | - | (5028 %) | (440 %) | (732 %) | (1786 %) | 67 % |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | - | - | (6635 %) | (722 %) | (845 %) | (1825 %) | (136 %) |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | - | - | 3644 % | 367 % | - | - | - |
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor | $0.0 | round |
| investor investor investor investor investor investor investor investor investor investor investor investor | $0.0 | round | |
| N/A | $0.0 | round | |
| investor investor | $0.0 | round | |
| investor | $0.0 | round | |
| investor investor investor investor investor investor investor investor investor investor investor | $0.0 | round | |
* | $40.0m | Post IPO Debt | |
| Total Funding | 000k | ||
RELATED LANDSCAPES AND LISTS
Related Content
Recent News about Taysha Gene Therapies
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.